RXi(美國)

RXi Pharmaceuticals

RXiPharmaceuticalswww.rxipharma.comRNAi技術(shù)平臺的創(chuàng)新療法RXiPharmaceuticalsCorporation(OTC:RXII)isabiotechnologycompanyfocusedondiscovering,developingandcommercializinginnovativetherapiesbasedonitsproprietary, next-generationRNAiplatform.TherapeuticsthatuseRNAinterference,or“RNAi,”havegreatpromisebecauseoftheirabilityto“silence,”ordown-regulate,theexpressionofaspecificgenethatmaybeoverexpressedinadiseasecondition.BuildingonthepioneeringworkofscientificfounderandNobelLaureateDr.CraigMello,RXi’sfirstRNAiproductcandidate,RXI-109,enteredintoRXi’sfirsthumanclinicaltrialin2012.RXI-109targetsconnectivetissuegrowthfactor(CTGF),akeyregulatoryoffibrosisandscarformation,andisinitiallybeingdevelopedtoreduceorinhibitscarformationintheskinfollowingsurgery.SpecialtiesDevelopmentofRNAibasedtherapeutics,RXI-109-l